Holen Sie sich die Stockscreener-App
7.22
1.83%
0.13
Handel nachbörslich:
7.29
0.07
+0.97%
Schlusskurs vom Vortag:
$7.09
Offen:
$7.17
24-Stunden-Volumen:
909.11K
Relative Volume:
0.66
Marktkapitalisierung:
$445.85M
Einnahmen:
$2.00M
Nettoeinkommen (Verlust:
$-51.04M
KGV:
-4.5725
EPS:
-1.579
Netto-Cashflow:
$-45.65M
1W Leistung:
+10.40%
1M Leistung:
+23.21%
6M Leistung:
+1.98%
1J Leistung:
+109.28%
1-Tages-Spanne:
$7.11
$7.45
1-Wochen-Bereich:
$6.50
$7.45
52-Wochen-Spanne:
$3.32
$11.41
Sagimet Biosciences Inc Stock (SGMT) Company Profile
Firmenname
Sagimet Biosciences Inc
Sektor
Branche
Telefon
(650) 561-8600
Adresse
155 BOVET RD., SUITE 303, SAN MATEO
Compare SGMT vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
7.22 | 437.82M | 2.00M | -51.04M | -45.65M | -1.579 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-26 | Eingeleitet | Rodman & Renshaw | Buy |
| 2026-02-03 | Eingeleitet | Guggenheim | Buy |
| 2026-01-28 | Eingeleitet | Barclays | Equal Weight |
| 2025-08-11 | Eingeleitet | Wedbush | Outperform |
| 2025-08-07 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-07-24 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-12-06 | Eingeleitet | Oppenheimer | Outperform |
| 2024-11-12 | Eingeleitet | UBS | Buy |
| 2024-06-28 | Herabstufung | Goldman | Buy → Neutral |
| 2024-05-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-03-25 | Eingeleitet | Leerink Partners | Outperform |
| 2023-08-08 | Eingeleitet | Goldman | Buy |
| 2023-08-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-08-08 | Eingeleitet | Piper Sandler | Overweight |
| 2023-08-08 | Eingeleitet | TD Cowen | Outperform |
Alle ansehen
Sagimet Biosciences Inc Aktie (SGMT) Neueste Nachrichten
SGMT Technical Analysis | Trend, Signals & Chart Patterns | SAGIMET BIOSCIENCES INC-A (NASDAQ:SGMT) - ChartMill
Why Are Analysts So Bullish on Sagimet Biosciences (SGMT) - Kavout
Wall Street Analysts Believe Sagimet Biosciences Inc. (SGMT) Could Rally 298.5%: Here's is How to Trade - Yahoo Finance
SGMT Stock Price, Quote & Chart | SAGIMET BIOSCIENCES INC-A (NASDAQ:SGMT) - ChartMill
SGMT Maintained by Citizens -- Price Target Lowered to $12 - GuruFocus
Sagimet Biosciences Is Maintained at Market Outperform by Citizens - Moomoo
Citizens JMP Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Cuts Target Price to $12 - Moomoo
Citizens cuts Sagimet Biosciences stock price target on valuation - Investing.com
Citizens cuts Sagimet Biosciences stock price target on valuation By Investing.com - Investing.com Australia
Sagimet Biosciences Shares Surge After Promising Phase 3 Acne Drug Results - MSN
Sagimet Biosciences (SGMT) price target increased by 15.00% to 29.86 - MSN
Number of shareholders of Sagimet Biosciences Inc.Series A – NASDAQ:SGMT - TradingView
Sagimet Biosciences (SGMT) CMO receives 264,759 stock options at $6.44 strike - Stock Titan
Sagimet Biosciences (SGMT) files Form 3 identifying Chief Medical Officer Andreas Grauer - Stock Titan
JonesTrading Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Cuts Target Price to $26 - Moomoo
Sagimet Biosciences: Making The Bull Case For Differentiated Denifanstat (NASDAQ:SGMT) - Seeking Alpha
Wedbush Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Sagimet Maintained at Buy as Strong Cash Runway and Advancing Acne Franchise Support Unchanged $28 Price Target - TipRanks
TD Cowen Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - GlobeNewswire
Biotech Sagimet to give fireside chat at NASDAQ investor event - Stock Titan
Sagimet Biosciences Releases Q1 2026 Financial Results - AlphaStreet
Sagimet Biosciences reports first quarter 2026 financial results and provides corporate updates - marketscreener.com
Sagimet Biosciences Reports First Quarter 2026 Financial Results And Provides Corporate Updates - TradingView
Sagimet Biosciences Secures $175M Financing and Plans Phase 3 Denifanstat Acne Trial in 2026 - Minichart
Sagimet Biosciences 1Q Loss/Shr 33c >SGMT - Moomoo
Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates - The Manila Times
Sagimet Biosciences Inc. 1Q 2026: Net loss $(10.7)M, EPS $(0.33) — 10-Q Summary - TradingView
Sagimet Biosciences (NASDAQ: SGMT) trims Q1 2026 loss and raises $175M - Stock Titan
After 40-year wait, Sagimet backs Phase 3 test of new oral acne drug - Stock Titan
Sagimet Biosciences | 10-Q: Q1 2026 Earnings Report - Moomoo
Sagimet Biosciences (NASDAQ: SGMT) cuts R&D spend and raises $175M equity - Stock Titan
TradingKey - TradingKey
Sagimet Biosciences shares jump 30% on acne trial expansion plans - MSN
Targeting the Source: Sagimet's Novel Drug Aims to Revolutionize Acne Treatment - BriefGlance
Does Sagimet Biosciences Inc. (SGMT) have the potential to rally 241.77% as Wall Street analysts expect? - MSN
Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society ... - Caledonian Record
Sagimet Biosciences to Present Mechanism of Action Data for - GlobeNewswire
Lab data back Sagimet’s experimental acne approach before Phase 3 trial - Stock Titan
Sagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy? - sharewise.com
Does Sagimet Biosciences Inc. (SGMT) Have the Potential to Rally 241.77% as Wall Street Analysts Expect? - Yahoo Finance
Sagimet Biosciences Price Target Raised to $49.00/Share From $28.00 by Canaccord Genuity - Moomoo
Sagimet Biosciences Is Maintained at Buy by Canaccord Genuity - Moomoo
JonesTrading Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Raises Target Price to $31 - Moomoo
CCORF Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Raises Target Price to $49 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Sagimet Biosciences | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Finanzdaten der Sagimet Biosciences Inc-Aktie (SGMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Sagimet Biosciences Inc-Aktie (SGMT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Chauche Thierry | Chief Financial Officer |
Feb 10 '26 |
Sale |
5.36 |
1,312 |
7,033 |
15,688 |
| Martins Eduardo Bruno | Chief Medical Officer |
Feb 10 '26 |
Sale |
5.36 |
3,640 |
19,511 |
103,296 |
| Rozek Elizabeth | Chief Legal & Admin. Officer |
Feb 10 '26 |
Sale |
5.36 |
2,622 |
14,054 |
190,959 |
| Kemble George | Executive Chairman |
Nov 20 '25 |
Sale |
7.69 |
37,688 |
289,979 |
81,005 |
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):